Search research articles
Contact Us
Filters
Showing results (61-70 of 162) with videos related to
Page
of 17
Sort By:
AIDS Research and Therapy
|
February 12, 2022
Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series
Samuel J Minkove, Grant Geiger, Josep M Llibre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 11, 2019
Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study
Boris Revollo, Sebastián Videla, Josep M Llibre, et al.
The Journal of Antimicrobial Chemotherapy
|
January 25, 2016
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial
Josep M Llibre, Hortensia Alvarez, Antonio Antela, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 15, 2015
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial
José R Santos, María Saumoy, Adrian Curran, et al.
Basic & Clinical Pharmacology & Toxicology
|
June 20, 2017
Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance
Purificación Cid-Silva, Josep M Llibre, Noelia Fernández-Bargiela, et al.
AIDS (London, England)
|
September 29, 2012
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
Esteban Martínez, Polyana M D'Albuquerque, Josep M Llibre, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 9, 2013
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification
Marta Massanella, Anna Esteve, Maria J Buzón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 23, 2025
Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
Josep M Llibre, Diego Ripamonti, Anna M Geretti, et al.
Open Forum Infectious Diseases
|
March 10, 2022
Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
Josep M Llibre, Pedro E Cahn, Janet Lo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 14, 2020
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
Ignacio Perez-Valero, Josep M Llibre, Antonella Castagna, et al.
Page
of 17
Search research articles
Search
Showing results (61-70 of 162) with videos related to
Sort By:
Page
of 17
AIDS Research and Therapy
|
February 12, 2022
Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series
Samuel J Minkove, Grant Geiger, Josep M Llibre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 11, 2019
Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study
Boris Revollo, Sebastián Videla, Josep M Llibre, et al.
The Journal of Antimicrobial Chemotherapy
|
January 25, 2016
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial
Josep M Llibre, Hortensia Alvarez, Antonio Antela, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 15, 2015
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial
José R Santos, María Saumoy, Adrian Curran, et al.
Basic & Clinical Pharmacology & Toxicology
|
June 20, 2017
Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance
Purificación Cid-Silva, Josep M Llibre, Noelia Fernández-Bargiela, et al.
AIDS (London, England)
|
September 29, 2012
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
Esteban Martínez, Polyana M D'Albuquerque, Josep M Llibre, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 9, 2013
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification
Marta Massanella, Anna Esteve, Maria J Buzón, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 23, 2025
Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
Josep M Llibre, Diego Ripamonti, Anna M Geretti, et al.
Open Forum Infectious Diseases
|
March 10, 2022
Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
Josep M Llibre, Pedro E Cahn, Janet Lo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
December 14, 2020
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
Ignacio Perez-Valero, Josep M Llibre, Antonella Castagna, et al.
Page
of 17